<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Korean Med Sci</journal-id>
      <journal-id journal-id-type="publisher-id">JKMS</journal-id>
      <journal-title-group>
        <journal-title>Journal of Korean Medical Science</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1011-8934</issn>
      <issn pub-type="epub">1598-6357</issn>
      <publisher>
        <publisher-name>The Korean Academy of Medical Sciences</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">16778412</article-id>
      <article-id pub-id-type="pmc">2729974</article-id>
      <article-id pub-id-type="doi">10.3346/jkms.2006.21.3.585</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Bucillamine-Induced Pemphigus Vulgaris in a Patient with Rheumatoid Arthritis and Polymyositis Overlap Syndrome</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Hur</surname>
            <given-names>Jin-Wuk</given-names>
          </name>
          <xref ref-type="aff" rid="A1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lee</surname>
            <given-names>Chang-Woo</given-names>
          </name>
          <xref ref-type="aff" rid="A2">*</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Yoo</surname>
            <given-names>Dae-Hyun</given-names>
          </name>
          <xref ref-type="aff" rid="A1"/>
        </contrib>
      </contrib-group>
      <aff id="A1">Division of Rheumatology, Department of Internal Medicine, The Hospital for Rheumatic Diseases, College of Medicine, Hanyang University, Seoul, Korea.</aff>
      <aff id="A2"><label>*</label>Department of Dermatology, College of Medicine, Hanyang University, Seoul, Korea.</aff>
      <author-notes>
        <corresp>Address for correspondence: Dae-Hyun Yoo, M.D. The Hospital for Rheumatic Diseases, Hanyang University Medical Center, 17 Haengdang-dong, Seongdong-gu, Seoul 133-792, Korea. Tel: +82.2-2290-9202, Fax: +82.2-2298-8231, <email>dhyoo@hanyang.ac.kr</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>6</month>
        <year>2006</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>21</day>
        <month>6</month>
        <year>2006</year>
      </pub-date>
      <volume>21</volume>
      <issue>3</issue>
      <fpage>585</fpage>
      <lpage>587</lpage>
      <history>
        <date date-type="received">
          <day>07</day>
          <month>3</month>
          <year>2005</year>
        </date>
        <date date-type="accepted">
          <day>20</day>
          <month>6</month>
          <year>2005</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2006 The Korean Academy of Medical Sciences</copyright-statement>
        <copyright-year>2006</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0">http://creativecommons.org/licenses/by-nc/3.0</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Bucillamine is a disease modifying anti-rheumatic drug, structurally similar to D-penicillamine. Although D-penicillamine-induced pemphigus has been not infrequently demonstrated, pemphigus associated with bucillamine was rarely reported. We describe a patient complicating pemphigus vulgaris after bucillamine treatment in rheumatoid arthritis (RA) and polymyositis (PM) overlap syndrome. PM and RA overlap syndrome was diagnosed three years ago and bucillamine was administrated for 20 months. Skin lesions including erythematous flaccid blisters on her chest, axillae, and back were occurred and were compatible with pemphigus vulgaris by typical pathology. Withdrawal from bucillamine and prednisolone treatment made rapid improvement of pemphigus lesions.</p>
      </abstract>
      <kwd-group>
        <kwd>bucillamine</kwd>
        <kwd>Pemphigus</kwd>
        <kwd>Polymyositis</kwd>
        <kwd>Arthritis, Rheumatoid</kwd>
        <kwd>adverse effects</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>D-penicillamine has been known as one of the agents that are able to induce pemphigus (<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>). Bucillamine [N-(2-mercapto-2-methylpropionyl)-L-cysteine] is a thiol compound contained two free sulfhydryl groups, whereas D-penicillamine has only one sulfhydryl radical (<xref ref-type="bibr" rid="B3">3</xref>). While drug-induced pemphigus was not infrequently demonstrated in association with d-penicillamine, it has rarely been reported with bucillamine and has never been reported in rheumatoid arthritis (RA) and polymyositis (PM) overlap syndrome. Hereby, we report a case of bucillamine-induced pemphigus vulgaris in a patient with RA and PM overlap syndrome.</p>
    </sec>
    <sec sec-type="cases">
      <title>CASE REPORT</title>
      <p>A 46-yr-old woman was referred to our rheumatology department due to polyarthralgia, and myalgia in May 2001. Soft tissue swelling and tenderness were bilaterally noted at the proximal interphalangeal and metacarpophalangeal joints with morning stiffness lasting at least 1 hr. Proximal motor weakness on upper arms and legs has insidiously developed over three months and findings of magnetic resonance image on both thighs were compatible with myositis. In addition, elevated level of muscle enzymes including creatine kinase (CK), aldolase, alanine aminotransferase (AST and ALT), and lactate dehydrogenase was shown. Antinuclear antibody was positive at 1:80 of speckled pattern, and 1:2,560 of cytoplasmic pattern. Auto-antibodies including anti-Jo-1, anti-RNP, anti-double stranded DNA, anti-Sm, and anti-SS-A/SS-B were absent. Level of rheumatoid factor was 3,420 IU/mL, but level of C3 and C4 was 97.9 mg/dL (normal range 79-152 mg/dL) and 30.8 mg/dL (normal range 16-38 mg/dL) respectively. Chest radiograph showed pattern of interstitial lung disease and pulmonary function test revealed significantly decreased DLCO. She was diagnosed as RA and PM overlap, and had been treated with prednisolone, azathioprine and non-steroidal anti-inflammatory drug since May 2001.</p>
      <p>Myositis became silent over time with above regimen, however she had continuous synovitis and joint pain on right knee and small joints on both hands. Her regimen was changed to cyclosporine and bucillamine. Twenty months later, the skin lesions occurred. She exhibited erythematous flaccid blisters on her chest, axillae, and back. Blisters consisted of erythematous patches and superficial erosions with turbid bullae suggesting pemphigus vulgaris (<xref ref-type="fig" rid="F1">Fig. 1</xref>). Nikolsky's sign was positive. Laboratory tests showed C-reactive protein 0.831 mg/dL (normal range &lt;0.8 mg/dL), and erythrocyte sedimentation rate 66 mm/hr. Liver function, renal function, CK, and electrolytes were normal. A skin biopsy revealed intraepidermal vesicle formation with acantholysis and the vesicle formation is suprabasal (<xref ref-type="fig" rid="F2">Fig. 2</xref>). Indirect immunofluorescence, performed by using serial dilutions of the patient's serum, demonstrated no IgG, IgA and C3 staining along epidermis and papillary dermis. Bucillamine was discontin-ued and the patient was placed on oral prednisolone 20 mg daily. The skin lesions rapidly improved, and disappeared within 2 months.</p>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>D-penicillamine and bucillamine have been used for patients with rheumatoid arthritis as a disease modifying anti-rheumatic drug. D-penicillamine can cause various autoimmune diseases including pemphigus, PM, and myasthenia gravis (<xref ref-type="bibr" rid="B4">4</xref>-<xref ref-type="bibr" rid="B6">6</xref>). Although bucillamine has a chemical structure similar to D-penicillamine, autoimmune diseases are rarely associated with bucillamine. Some cases of bucillamine-induced interstitial lung disease, nephropathy, and myasthenia gravis were described (<xref ref-type="bibr" rid="B7">7</xref>-<xref ref-type="bibr" rid="B9">9</xref>). It was reported that the incidence of D-penicillamine-induced pemphigus was about 7% (<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B10">10</xref>) and mean duration until the onset of pemphigus was 11 to 13 months (<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref>). It frequently presents as an urticarial, annular, or moniliform erythematous prodrome. Scaly crusted patches, vesicles, and bullae are developed subsequently (<xref ref-type="bibr" rid="B5">5</xref>). The mechanism of thiol drugs-induced pemphigus is still obscure. It has been suggested that the epidermal cell surface proteins play a role as an antigen to the host through a sulfhydryl radical and other unknown factors (<xref ref-type="bibr" rid="B1">1</xref>). In D-penicillamine- induced pemphigus, the prevalence of IgG and IgA antibodies directed against the intercellular region is lower than that in spontaneously occurring pemphigus (<xref ref-type="bibr" rid="B13">13</xref>). It has been shown that these antibodies might not be detected in some cases of drug-induced pemphigus like our case (<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B14">14</xref>). To date, only 2 cases of bucillamine-induced pemphigus were reported in English literature. One was drug-induced pemphigus foliaceus with features of pemphigus vulgaris and the other was subcorneal pustular dermatosis-type IgA pemphigus induced by thiol drugs (<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B14">14</xref>).</p>
      <p>The discontinuation of D-penicillamine may be inadequate in treatment because it frequently fails to stop disease progression.Initial dose of corticosteroid is typically about 0.75-1 mg/kg/day. It has been suggested that high-dose or pulse therapy with steroids usually clears blisters promptly. Prednisolone at a lower dose of 20-30 mg/day can maintain these patients without blistering but other adjuvant immunosuppressive drugs is need to achieve steroid-sparing effect or prevention of relapse (<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B16">16</xref>). Blisters of our patient disappeared rapidly with corticosteroid treatment and discontinuation of bucillamine. Relapse was not found during the subsequent 6 months.</p>
      <p>In conclusion, bucillamine may cause pemphigus even at a low rate therefore we have to keep in mind that skin lesions with blisters should be carefully investigated in patients with bucillamine treatment.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yung</surname>
              <given-names>CW</given-names>
            </name>
            <name>
              <surname>Hambrick</surname>
              <given-names>GW</given-names>
              <suffix>Jr</suffix>
            </name>
          </person-group>
          <article-title>D-Penicillamine--induced pemphigus syndrome</article-title>
          <source>J Am Acad Dermatol</source>
          <year>1982</year>
          <volume>6</volume>
          <fpage>317</fpage>
          <lpage>324</lpage>
          <pub-id pub-id-type="pmid">7068961</pub-id>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Levy</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Fisher</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Alter</surname>
              <given-names>JN</given-names>
            </name>
          </person-group>
          <article-title>Penicillamine: review and cutaneous manifestations</article-title>
          <source>J Am Acad Dermatol</source>
          <year>1983</year>
          <volume>8</volume>
          <fpage>548</fpage>
          <lpage>558</lpage>
          <pub-id pub-id-type="pmid">6222087</pub-id>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hirohata</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lipsky</surname>
              <given-names>PE</given-names>
            </name>
          </person-group>
          <article-title>Regulation of B cell function by bucillamine, a novel disease-modifying antirheumatic drug</article-title>
          <source>Clin Immunol Immunopathol</source>
          <year>1993</year>
          <volume>66</volume>
          <fpage>43</fpage>
          <lpage>51</lpage>
          <pub-id pub-id-type="pmid">8440072</pub-id>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ciompi</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Marchetti</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Bazzichi</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Puccetti</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Agelli</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>D-penicillamine and gold salt treatments were complicated by myasthenia and pemphigus, respectively, in the same patient with rheumatoid arthritis</article-title>
          <source>Rheumatol Int</source>
          <year>1995</year>
          <volume>15</volume>
          <fpage>95</fpage>
          <lpage>97</lpage>
          <pub-id pub-id-type="pmid">8588126</pub-id>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shapiro</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Jimenez</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Werth</surname>
              <given-names>VP</given-names>
            </name>
          </person-group>
          <article-title>Pemphigus vulgaris induced by D-penicillamine therapy in a patient with systemic sclerosis</article-title>
          <source>J Am Acad Dermatol</source>
          <year>2000</year>
          <volume>42</volume>
          <fpage>297</fpage>
          <lpage>299</lpage>
          <pub-id pub-id-type="pmid">10642693</pub-id>
        </element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jenkins</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Hull</surname>
              <given-names>RG</given-names>
            </name>
            <name>
              <surname>Thomas</surname>
              <given-names>AL</given-names>
            </name>
          </person-group>
          <article-title>D-penicillamine and polymyositis: the significance of the anti-Jo-1 antibody</article-title>
          <source>Br J Rheumatol</source>
          <year>1993</year>
          <volume>32</volume>
          <fpage>1109</fpage>
          <lpage>1110</lpage>
          <pub-id pub-id-type="pmid">8252325</pub-id>
        </element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Negishi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kaga</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kasama</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hashimoto</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Fukushima</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Yamagata</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Tabata</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kobayashi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ide</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Takahashi</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Lung injury associated with bucillamine therapy</article-title>
          <source>Ryumachi</source>
          <year>1992</year>
          <volume>32</volume>
          <fpage>135</fpage>
          <lpage>139</lpage>
          <pub-id pub-id-type="pmid">1595005</pub-id>
        </element-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sawa</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Ubara</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Hara</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hideyuki</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Tagami</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Yokoyama</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Takemoto</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Yamada</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mori</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Mikami</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Tachibana</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Nakase</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>A case of rheumatoid arthritis with bucillamine-induced myasthenia gravis treated by immunoadsorption therapy</article-title>
          <source>Ryumachi</source>
          <year>1999</year>
          <volume>39</volume>
          <fpage>33</fpage>
          <lpage>38</lpage>
          <pub-id pub-id-type="pmid">10332215</pub-id>
        </element-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Obayashi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Uzu</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Harada</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Yamato</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Takahara</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Yamauchi</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Clinical course of bucillamine-induced nephropathy in patients with rheumatoid arthritis</article-title>
          <source>Clin Exp Nephrol</source>
          <year>2003</year>
          <volume>7</volume>
          <fpage>275</fpage>
          <lpage>278</lpage>
          <pub-id pub-id-type="pmid">14712356</pub-id>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brenner</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Wolf</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ruocco</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>Drug-induced pemphigus. I. A survey</article-title>
          <source>Clin Dermatol</source>
          <year>1993</year>
          <volume>11</volume>
          <fpage>501</fpage>
          <lpage>505</lpage>
          <pub-id pub-id-type="pmid">8124639</pub-id>
        </element-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ho</surname>
              <given-names>VC</given-names>
            </name>
            <name>
              <surname>Stein</surname>
              <given-names>HB</given-names>
            </name>
            <name>
              <surname>Ongley</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>McLeod</surname>
              <given-names>WA</given-names>
            </name>
          </person-group>
          <article-title>Penicillamine induced pemphigus</article-title>
          <source>J Rheumatol</source>
          <year>1985</year>
          <volume>12</volume>
          <fpage>583</fpage>
          <lpage>586</lpage>
          <pub-id pub-id-type="pmid">3900395</pub-id>
        </element-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kishimoto</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Iwatsuki</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Akiba</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Motoki</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Kaneko</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Subcorneal pustular dermatosis-type IgA pemphigus induced by thiol drugs</article-title>
          <source>Eur J Dermatol</source>
          <year>2001</year>
          <volume>11</volume>
          <fpage>41</fpage>
          <lpage>44</lpage>
          <pub-id pub-id-type="pmid">11174137</pub-id>
        </element-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bialy-Golan</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Brenner</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Penicillamine-induced bullous dermatoses</article-title>
          <source>J Am Acad Dermatol</source>
          <year>1996</year>
          <volume>35</volume>
          <fpage>732</fpage>
          <lpage>742</lpage>
          <pub-id pub-id-type="pmid">8912569</pub-id>
        </element-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ogata</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Nakajima</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Ikeda</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Yamamoto</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Amagai</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hashimoto</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kodama</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Drug-induced pemphigus foliaceus with features of pemphigus vulgaris</article-title>
          <source>Br J Dermatol</source>
          <year>2001</year>
          <volume>144</volume>
          <fpage>421</fpage>
          <lpage>422</lpage>
          <pub-id pub-id-type="pmid">11251589</pub-id>
        </element-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kitajima</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Current and prospective understanding of clinical classification, pathomechanisms and therapy in pemphigus</article-title>
          <source>Arch Dermatol Res</source>
          <year>2003</year>
          <volume>295</volume>
          <issue>Suppl 1</issue>
          <fpage>17</fpage>
          <lpage>23</lpage>
        </element-citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Piamphongsant</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ophaswongse</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Treatment of pemphigus</article-title>
          <source>Int J Dermatol</source>
          <year>1991</year>
          <volume>30</volume>
          <fpage>139</fpage>
          <lpage>146</lpage>
          <pub-id pub-id-type="pmid">2001906</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="F1" position="float">
      <label>Fig. 1</label>
      <caption>
        <p>Erythematous patches and superficial erosions with pustular bullae on axillae and back of the patient.</p>
      </caption>
      <graphic xlink:href="jkms-21-585-g001"/>
    </fig>
    <fig id="F2" position="float">
      <label>Fig. 2</label>
      <caption>
        <p>Skin biopsy shows acantholysis at the suprabasal layer, as well as at the upper layers of epidermis (H&amp;E, &#xD7;400).</p>
      </caption>
      <graphic xlink:href="jkms-21-585-g002"/>
    </fig>
  </floats-group>
</article>
</pmc-articleset>
